Exforge: Phase IV data

In an 8-week, double-blind, U.S. and European Phase IV study in 646 patients with MSSBP >=160 mmHg, Exforge met the primary endpoint of reducing MSSBP vs. amlodipine monotherapy at week 4 (30.1 mmHg v...